1.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: Not specified
Sponsor: NHLBI
Protocol IDs: 557, U01 HL072305-01, HL072268, HL072291, HL072196, HL072248, HL072191, HL072305, HL072028, HL072072, HL072355, HL072283, HL072346, HL072331, HL072290, NCT00627393
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI
Protocol IDs: NCI-01-C-0125F, NCT00020592
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: NHLBI-02-H-0250, NCT00047060
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI
Protocol IDs: FHCRC-1655.00, 5430, NCT00052520
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2005-0508, NCT00402558
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EK126092000, NCT00460629
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Other
Protocol IDs: CIK#2/2007, NMRC/1097/2006, NCT00460694
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0210, 07-C-0210, NCT00537069
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-001-HMC, NCT00558675
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 75
Sponsor: NCI
Protocol IDs: NCI-08-C-0051, 08-C-0051, NCI-P06049, NCT00608166
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 20406, NCT00674427
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: AMC-UUCM-2008-0383, 2008-0383, NCT00823524
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ARL-GT 2005, NCT00858793
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-001-HM, NCT00861965
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-97-H-0196, NCT00003553
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-99-H-0050, NCT00003838
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 5 to 75
Sponsor: NCI
Protocol IDs: RPCI-RP-0105, NCT00053989, RP 01-05
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-11/0105, EU-20234, NCT00056095
|
|
25.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-04-C-0055, NCT00077480
|
